Table 2.

a. Multivariate Analyses of Prognostic Factors for Advanced Stage Clear Cell Ovarian Cancer
	Disease Progression			Death
	HR	95% C.I.	P	HR	95% C.I.	P
Age (increase 10 yrs)	1.13	0.93 – 1.38	0.23	1.28	1.03 – 1.58	0.03
GOG PS 1			0.08			0.67
0	1.0			1.0
1 or 2	1.50	0.95 – 2.37		1.11	0.68 – 1.82
Stage/debulking 2			<0.001			<0.001
III optimal Micro	1.0			1.0
III optimal Gross	1.25	0.70 – 2.24		1.43	0.77– 2.65
III suboptimal/IV	3.50	2.13 – 5.75		2.71	1.61– 4.57

b. CA-125 Levels and Clinical Outcomes for Advanced Stage Clear Cell Ovarian Cancer
	Disease Progression			Death
	HR	95% C.I.	P	HR	95% C.I.	P
CA 125 at pre-treatment
High vs. Normal	1.95	0.84 – 4.54	0.12	1.42	0.57 – 3.53	0.45
CA 125 at end of treatment
High vs. Normal	3.34	1.96 – 5.68	<0.001	2.41	1.39 – 4.19	0.002

Hazard ratio (HR) estimated from Cox model.

¹PS: performance status.

²III-optimal Micro: stage III without gross tumor residual after debulking; III-optimal Gross: stage III with a tumor residual >0 - ≤1cm after debulking; III-suboptimal: stage III with a tumor residual>1cm after debulking.

CA-125 at pre-chemotherapy or during treatment evaluated separately by Cox regression models, HR estimated adjusted for age, performance status and FIGO stage/volume residual; CA 125 at pre-treatment defined as the measurement at pre-chemotherapy following surgical debulking; CA-125 at end of treatment defined as the last measurement of CA-125 level over treatment period; CA-125≤ 35 u/ml defined as normal and CA-125>35 u/ml defined as high